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Methods: Sixty isolates were identiﬁed as Acinetobacter
species. The isolates were tested for antibiotic resistance by
disc diffusion method for 12 antimicrobials. The presence of
aphA6, aacC1 aadA1, and aadB genes were detected using
PCR.
Results: From the isolated Acinetobacter spp. the highest
resistance rate showed against amikacin, tobramycin, and
ceftazidim, respectively; while isolated bacteria were more
sensitive to ampicillic/subactam. More than 66% of the iso-
lates were resistant to at least three classes of antibiotics,
and 27.5% of MDR strains were resistant to all seven tested
classes of antimicrobials. The higher MDR rate presented
in bacteria isolated from the ICU and blood samples. More
than 60% of the MDR bacteria were resistance to amikacin,
ceftazidim, ciproﬂoxacin, piperacillin/tazobactam, doxy-
cycline, tobramycin and levoﬂoxacin. Also, more than
60% of the isolates contained phosphotransferase aphA6,
and acetyltransferase genes aacC1, but adenylyltransferase
genes aadA1 (41.7%), and aadB (3.3%) were less prominent.
In this study 21.7% of the strains contain three aminoglyco-
side resistance genes (aphA6, aacC1 and aadA1).
Conclusion: The rising trend of resistance to amino-
glycosides poses an alarming threat to treatment of such
infections. The ﬁndings showed that clinical isolates of
Acinetobacter spp. in our hospital carrying various kinds of
aminoglycoside resistance genes.
doi:10.1016/j.ijid.2010.02.1563
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Incidence of Carbapanemase Resistance Gene (KPC)
among Klebsiella pneumoniae isolates and its Clinical
Implications
B. Yegneswaran ∗, W. Numsuwan, D. Alcid
Drexel University College of Medicine / St Peter’s University
Hospital, New Brunswick, NJ, USA
Background: Carbapenem antibiotics (Imipenem,
Ertapenem, and Meropenem) idicated for infections caused
by extended-spectrum {beta}-lactamase (ESBL) carrying
pathogens. Carbapenem resistance has been unusual in
isolates of Klebsiella pneumoniae. The aim of this study
is to identify the prevalence of KPC positive Klebsiella
pneumoniae, and it’s clinical signiﬁcance.
Methods: All isolates of Klebsiella pneumoniae species
from October 1, 2007 to September 30, 2009 were tested
for the presence of KPC gene using the modiﬁed Hodge test.
Medical records of patients with KPC were studied.
Results: Over the period of two-years 40,309 samples
were submitted for culture and sensitivity, out of which
7,836 were positive. Of the positives, there were 106 iso-
lates of K pneumoniae and 11 were ESBL positive. Of
the ESBL producing isolates, 8 carried the Carbapenem-
hydrolyzing -lactamase. Of the eight, three isolates were
reported as being susceptible to Imipenem. Although all
the eight isolates were resistant using the Hodge test.
Piperacillin/Tazobactam (PT) and Vancomycin were the
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ntibiotic used 7 of the 8 patients prior to isolation
f Klebsiella pneumoniae resistant to Carbapenems. One
atient was excluded in outcome as one patient’s sam-
le was clinically thought to be a contaminant was not
reated. 3 patients in whom resistance to carbapenem was
eported had their antibiotic was changed to Tigecycline
nd Polymyxin B resulting in clinical improvement. Of the
emaining 4 patients who were reported as sensitive to car-
apenem three patients had to undergo a repeat surgery due
o clinical deterioration and one patient clinically died.
Conclusion: The incidence of KPC gene at our hospi-
al was 7.5%. KPC positive isolatesare rapidly emerging
athogens. It is very important to keep this organism in mind
s if not treated there is a 100% probability of having a poor
utcome. There is a complete cross resistance to all Car-
apenems containing KPC, therefore if KPC is present, the
pneumoniae will be resistant to all Carbapenem regard-
ess of the routine susceptibility testing as shown in three
solates that are KPC positive but susceptible to Imipenem.
urrent automated systems used for susceptibility testing
ay not accurately identify all these isolates. We must also
ontrol the use of antibiotics specially PT to prevent emer-
ence of KPC positive organisms.
oi:10.1016/j.ijid.2010.02.1564
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n vitro activity of Tigecycline against molecularly deﬁned
arbapenemase producing Acinetobacter baumannii
. Hackel1,∗, P. Higgins2, H. Seifert2, S. Bouchillon1, B.
ohnson1, R. Badal1, J. johnson1, D. Hoban1, S. Hawser3,
. Dowzicky4
International Health Management Associates, Inc.,
chaumburg, IL, USA
Institute for Medical Microbiology, Cologne, Germany
IHMA Europe Sàrl, Epalinges, Switzerland
Pﬁzer Inc, Collegeville, PA, USA
Background: Acinetobacter baumannii are important
pportunistic pathogens with increasing rates of multi-
ntibiotic resistance due to both intrinsic and acquired
echanisms. Carbapenems are often used to treat these
nfections, however carbapenem resistance is increasingly
eported, leaving few therapeutic options. This resistance
s most often associated with acquired or intrinsic OXA-
roup carbapenemase production. While A. baumannii carry
he intrinsic OXA-51-like carbapenemase gene, carbapenem
esistance has only been associated with these genes when
he insertion sequence ISAba1 is upstream. In this study, we
valuated the in vitro activity of tigecycline against geneti-
ally deﬁned A. baumannii from the Tigecycline Evaluation
urveillance Trial.Methods: A total 352 imipenem resistant Acinetobacter
aumanii from 35 countries (2004 to 2006) were evaluated.
ICs were determined by broth microdilution and inter-
reted according to CLSI guidelines. Carbapenemase genes
ere detected by multiplex PCR.
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Results: All isolates tested in this study contained an OXA-
1-like gene. Additional genotypes are listed below.
N TIG MIC50
(mcg/ml)
TIG MIC50
(mcg/ml)
Range
XA-23 161 1 2 0.12-4
XA-40 39 0.5 1 0.25-4
XA-58 107 0.5 1 0.12-4
SAbal-OXA-51 190 1 2 0.12-4
Conclusion: Tigecycline demonstrated excellent in vitro
ctivity against carbapenem resistant A. baumannii regard-
ess of carbapenemase type. Tigecycline’s in vitro activity
gainst isolates with either intrinsic ISAba1-OXA-51 or the
cquired oxacillinases (OXA-23, OXA-40 and OXA-58) sug-
ests that it may be effective against resistant isolates of
his clinically important pathogen.
oi:10.1016/j.ijid.2010.02.1565
3.010
olecular typing of multi-drug resistant Acinetobacter
aumannii from London hospitals
. Wareham ∗, D. Bean
Queen Mary University London, London, United Kingdom
Background: Acinetobacter baumannnii has emerged
s a major nosocomial pathogen causing outbreaks of
nfection in the immunosuppressed and critically ill world-
ide. A number of molecular typing techniques have
een developed for use in both local surveillance and
lobal epidemiological studies. We applied a recently
escribed multi-locus sequence typing (MLST) scheme to
ulti-drug resistant A. baumannii (MDRAB) recovered from
ondon Hospitals in comparison with other molecular
ethods.
Methods: Sixteen MDRAB were identiﬁed using multiplex
CR for OXA-carbapenemases and included representatives
reviously assigned to the UK ‘South East’, OXA-23 (1) and
XA-23 (2) clones. Stains were typed using pulsed ﬁeld gel
lectrophoresis (PFGE), randomampliﬁed polymorphic DNA-
CR (RAPD), a multiplex PCR typing (MPT) scheme (ompA,
suE and blaOXA-51 like genes) and an A. baumannii MLST
cheme (gltA, gyrB, gdhB, recA, cpn60, gpi, rpoD).
Results: Five clearly distinguishable proﬁles were
bserved using PFGE and six with RAPD. MPT typing assigned
ll but one of the strains (OXA-23 (2) representative) to
roup 1. Four allelic proﬁles (sequence types ST) were
btained using MLST, two of which appeared to be novel.
omparison of results revealed isolates designated ‘South
ast’ clone by PFGE / RAPD belonged to the previously
escribed ST22 and those designated OXA-23 (1) to ST53.
he allelic proﬁle of the OXA-23 clone 2 strain was novel
nd contained a new gyrB allele.
Conclusion: Molecular techniques were comparable for
yping UK MDRAB. Isolates belonging to ST22, (found pre-
iously in Italy, Portugal, Czech Republic, China, Korea
nd Australia) and isolates belonging to ST53 (found previ-
usly in Italy) were the most frequently types, highlighting
he widespread dissemination of these clones. Two novel
t
c
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equence types were identiﬁed and are undergoing further
nvestigation.
oi:10.1016/j.ijid.2010.02.1566
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merging multi drug-resistant Acinetobacter in Iran:
tudy of 800 cases
. Abbasi 1, D. Yadegarynia2,∗, M. Mardani2, B. Frasinejad2,
. Yaghubi2, S. Gholamin2
Shaheed Beheshti Medical University, Tehran, Iran, Islamic
epublic of
Shaheed Beheshti Medical University, tehran, Iran, Islamic
epublic of
Background: Acinetobacter baumannii is a multi drug
esistant organism associated with high morbidity and mor-
ality. It is an emerging nosocomial pathogen in many parts
f the world. The aim of the present study was to review the
ncidence of Acinetobacter in several hospitals in Tehran,
ran and also to ﬁnd out pattern of antibiotic resistance of
cinetobacter. We published primary results of this study
hen it was consisted of 100 samples. It was accepted in
8th Annual ICAAC/ 46th Annual IDSA congress, Oct. 2008.
Methods: In a retrospective study we detected 800 posi-
ive cultures of Acinetobacter from 800 patients in different
ards of several tertiary care hospitals in Tehran, Iran. Disk
iffusion method was used to determine the resistance of
solated Acinetobacter baumannii. Antimicrobial sensitiv-
ty to 14 available antibiotics was analyzed. The following
ntibiotics were tested: cefriaxone, cefotaxime, cef-
azidime, cefepime, trimethoprim-sulfamethoxazole, gen-
amicin, tobramycin, amikacin, ciproﬂoxacine, oﬂoxacine,
mipenem, meropenem, piperacillin-tazobactam and tige-
ycline.
Results: The most frequently sites of infection were
ound, respiratry tract, blood stream, and urinary tract.
he most increminated wards were burn and intensive care
nit with a high prevalence of wound infection, pneumo-
ia and septicemia due to Acinetobacter. Acinetobacter was
solated from wound in 58.9%, tracheal discharge 9.2%, spu-
um in 7.1%, urine in 6.6%, blood in 5.8%, CSF in 3.4%, pleural
uid in 2%, tip of catheter (CV line) in 0.6% and brochoalve-
lar lavage (BAL) in 0.2%.
Acinetobacter baumannii showed resistance to cefri-
xone, cefotaxime, ceftazidime and cefepime more
han 90%. Resistance to gentamicin and trimethoprim-
ulfamethoxazole were more than 80%. Resistance to
mikacin, imipenem and ciproﬂoxacine were 72.7%,
0.5% and 45.7% respectively. Tigecycline, piperacillin-
azobactam, tobramycin and oﬂoxacine were evaluated in
00 samples. Sensitivity to tobramycin and oﬂoxacine were
8.9% and 25.3% respectively. Tigecycline and piperacillin-
azobactam were active against 100% and 74% of the strains
espectively.
Conclusion: Acinetobacter baumanii is an increasingly
solated pathogen in Iran. Prevalence of carbapenem resis-
ant acinetobacter is high in our study. Newer antimicrobial
ompound is needed for treatment of this infection.
oi:10.1016/j.ijid.2010.02.1567
